NRx Pharmaceuticals
Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuropsychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.
This person is not in the org chart
This person is not in any offices
NRx Pharmaceuticals
NRx is a clinical-stage pharmaceutical company that is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.